Østrogenplastre til unge og unge voksne kvinder med cystisk fibrose (STURDY)
Transdermal østradiol til unge og unge voksne kvinder med CF
The goal of this study is to learn about the role of estrogen and other hormones in bone development in adolescent and young adult women with cystic fibrosis (CF). The study has two main components, an observational study and a feasibility sub-study. The main questions it aims to answer are:
- How do different forms of hormonal contraception (e.g. birth control pill or other progesterone only methods) impact bone health?
- Is a study of transdermal estradiol (estrogen skin patches) feasible in this group?
- How does transdermal estradiol impact bone health and quality of life?
Participants in the observational study will have three study visits (baseline, 6 months, and 12 months). At all visits, participants will have blood drawn and will complete questionnaires. At the baseline and 12 month visits, participants will additionally have x-rays and DXAs (bone density assessment). Between visits, participants will complete brief questionnaires. Researchers will compare various measurements over time to assess the impact of different forms of hormonal contraception.
Participants in the feasibility sub-study will apply transdermal estradiol patches once weekly for 12 months, fill out brief quality-of-life surveys in between study visits, and complete blood draws and questionnaires at four study visits (baseline, 3 months, 6 months, and 12 months). The participants will also have x-rays and DXAs performed at the baseline and 12 month visits. Researchers will examine changes in various measurements to determine the impact of transdermal estradiol.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 4
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Cynthia Wang
- Telefonnummer: 410-929-3056
- E-mail: cwang202@jh.edu
Studiesteder
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Rekruttering
- Johns Hopkins
-
Ledende efterforsker:
- Malinda Wu, MD, MSc
-
Kontakt:
- Cynthia Wang
- Telefonnummer: 410-929-3056
- E-mail: cwang202@jh.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Observational Study:
Inclusion Criteria:
- CF Diagnosis
- Females who have had at least 1 menstrual cycle
- Planning to use same formulation of estrogen supplementation (or none) for duration of study
Exclusion Criteria:
- Use of anti-osteoporosis therapy including anti-resorptives such as bisphosphonates or anabolic agents such as teriparatide or denosumab
- Conditions in which bone loss is known to be present or expected to occur, such as lactation
- Pregnant or planning to become pregnant
- In the opinion of the CF care team or study investigators participant should not participate in the study
- Inability to provide informed consent/assent
Feasibility Sub-Study:
Inclusion Criteria:
- All of above and
- <35 years old
- At least 2 years after first menstrual cycle
- Symptoms of low estrogen and/or low serum estradiol levels (< 50 pg/mL)
Exclusion Criteria:
- All of above and
- Contraindications to transdermal estradiol
- Current use of systemic estrogen (such as estrogen-containing oral contraceptive pill)
- Previous lung or liver transplant
- Use of chronic systemic glucocorticoids
- Severe vitamin D deficiency (serum 25(OH)D < 6 ng/mL)
- Conditions increasing risk of clot: history of previous deep vein thrombus or pulmonary embolism, current immobility, current peripherally inserted central catheter or mediport, known hypercoagulable condition
- Baseline study visit falls between 1 and 8 weeks after initiation of CF transmembrane receptor (CFTR) modulator
- Currently in pulmonary exacerbation
- Recent antibiotic use within the past 4 weeks for an acute pulmonary exacerbation
- Unwilling or unable to use a non-estrogen containing method of contraception such as barrier, abstinence, or progesterone-only method
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Ingen indgriben: Observational Study
Participants will complete three study visits (baseline, 6 months, and 12 months) involving DXAs (bone density assessment), x-rays, blood draws, and questionnaires. |
|
|
Eksperimentel: Transdermal Estradiol/Cyclic Progesterone
Participants will apply transdermal estradiol patches (0.1 mg/day) weekly for 12 months following baseline study visits. Participants not already using a progesterone-containing contraceptive will also take progesterone (200 mg) for 10 days per month. |
Transdermal estradiol 0.1 mg/day, applied once weekly
Andre navne:
Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring i lændehvirvelsøjlens knoglemineraltæthed vurderet ved dobbelt-energi røntgenabsorptiometri (DXA)
Tidsramme: Baseline og 12 måneder
|
Baseline og 12 måneder
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in serum procollagen type I intact N-terminal propeptide (P1NP) levels (mcg/L)
Tidsramme: Baseline and 12 months
|
P1NP is a marker of bone turnover. |
Baseline and 12 months
|
|
Change in serum C-terminal telopeptide of type I collagen (CTX-1) levels (pg/mL)
Tidsramme: Baseline and 12 months
|
CTX-1 is a marker of bone turnover. |
Baseline and 12 months
|
|
Change in quality of life as assessed by Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS) questionnaire
Tidsramme: Baseline and 12 months
|
CFRSD-CRISS is a brief survey to assess quality of life of people with cystic fibrosis that will be taken by participants twice per month. The questionnaire is scored from 0-100 with higher scores indicating increased symptom severity. |
Baseline and 12 months
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Study procedure completion rate
Tidsramme: Evaluated at completion of study, approximately two years
|
Percentage of participants enrolled in study who complete all study procedures. |
Evaluated at completion of study, approximately two years
|
|
Acceptability as determined by participant report
Tidsramme: Across 12 months of study participation per participant
|
Acceptability during study participation by 5 point Likert scale, with a score or 3 or greater considered acceptable. |
Across 12 months of study participation per participant
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Malinda Wu, MD, MSc, Johns Hopkins University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Muskuloskeletale sygdomme
- Genetiske sygdomme, medfødte
- Metaboliske sygdomme
- Luftvejssygdomme
- Sygdomme i fordøjelsessystemet
- Lungesygdomme
- Spædbarn, Nyfødt, Sygdomme
- Pancreassygdomme
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Ernæringsmæssige og metaboliske sygdomme
- Osteoporose
- Cystisk fibrose
- Knoglesygdomme
- Knoglesygdomme, metaboliske
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Polycykliske forbindelser
- Graviditet
- Steroider
- SMUSED-RING-forbindelser
- Estrenes
- Estraner
- Estradiol kongenere
- Gonadale steroidhormoner
- Gonadale hormoner
- Graviderede
- Gravidser
- Corpus luteum hormoner
- Progesteron -kongenere
- Østradiol
- Progesteron
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- IRB00307525
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .